Donepezil Hydrochloride Tablet, Film Coated
Product Images NDC 0904-6478

Product Visual Gallery

This gallery contains 15 technical images submitted to the FDA as part of the official labeling for Donepezil Hydrochloride (NDC 0904-6478). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Major Pharmaceuticals, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

A25f22d4 7808 4843 Ac48 7bd15473f6ba 00

Donepezil Hydrochloride Tablets, USP is a prescription medication used for the treatment of mild to moderate dementia caused by Alzheimer's disease. This medication comes in a pack of 100 tablets with each tablet containing 10mg of the active ingredient. The dosage should be determined by a healthcare professional. The manufacturer of Donepezil Hydrochloride Tablets is Gmaior.*

FDA Label Image

A25f22d4 7808 4843 Ac48 7bd15473f6ba 01

This is a description of a medication that contains Donepezil Hydrochloride in the form of Unit Dose Tablets. The medication is labeled with an NDC code and comes in a bottle containing 100 tablets. The pharmacist should dispense it with a patient information sheet. The rest of the text appears to be illegible due to errors.*

FDA Label Image

De82e6d7 F231 449a A2aa 91e26eb50774 01

FDA Label Image

De82e6d7 F231 449a A2aa 91e26eb50774 02

This is a table showing the change from baseline in ADAS-cog over the course of 18 weeks of drug treatment. The table includes data for Donepezil Hydrochloride Tablets at 5mg/day and 10mg/day and for placebo. The data is divided into Clinical Improvement and Clinical Decline categories. The table also includes the weeks of treatment on the x-axis.*

FDA Label Image

De82e6d7 F231 449a A2aa 91e26eb50774 03

Cumulative percentage of patients experiencing improvement or no change in ADAS-cog scores over time for donepezil hydrochloride tablets (5mg/day and 10mg/day) compared to a placebo group. The graph shows that a higher percentage of patients treated with donepezil hydrochloride tablets had improvements in cognitive function compared to those who received a placebo.*

FDA Label Image

De82e6d7 F231 449a A2aa 91e26eb50774 04

This is a chart depicting the percentage of patients who experienced improvement or worsening in their CIBIC-plus rating after taking either BN Donepezil Hydrochloride Tablets at either 10 mg/day or 5 mg/day or a placebo. The chart also includes a scale for determining the level of improvement, with options ranging from "Markedly Improved" to "Markedly Worse."*

FDA Label Image

De82e6d7 F231 449a A2aa 91e26eb50774 05

This appears to be a graph showing the ADAS-cog change from baseline for three different groups - one group taking Donepezil hydrochloride tablets 10mg/day, one group taking Donepezil hydrochloride tablets 5mg/day, and a placebo group. There are four time points labeled on the x-axis - 0, 3, 6, and 9 weeks of drug treatment. The y-axis shows the ADAS-cog change from baseline, with mean values and standard errors depicted. The graph also includes labels for "Clinical Improvement" and "Clinical Decline".*

FDA Label Image

De82e6d7 F231 449a A2aa 91e26eb50774 06

This is a chart displaying the cumulative percentage of patients who experienced different levels of change in ADAS-COG (Alzheimer's Disease Assessment Scale-Cognitive Subscale) score from baseline after being treated with Donepezil Hydrochloride Tablets at either 5mg/day or 10mg/day. The chart shows that a higher percentage of patients who received treatment with Donepezil Hydrochloride Tablets at 5mg/day and 10mg/day experienced a decrease in ADAS-COG score compared to patients who received a placebo. The chart also displays the percentage of patients who experienced no change in ADAS-COG score.*

FDA Label Image

De82e6d7 F231 449a A2aa 91e26eb50774 07

FDA Label Image

De82e6d7 F231 449a A2aa 91e26eb50774 08

FDA Label Image

De82e6d7 F231 449a A2aa 91e26eb50774 09

FDA Label Image

De82e6d7 F231 449a A2aa 91e26eb50774 10

This is a figure showing the time course of change of ADCS-ADL-Severe score for patients who completed 6 months of treatment. It compares the clinical improvement and decline of patients using donepezil hydrochloride tablets 10mg/day and placebo. The x-axis shows the months of drug treatment while the y-axis represents the score.*

FDA Label Image

De82e6d7 F231 449a A2aa 91e26eb50774 11

The text provides a graph that shows the cumulative percentage of patients for Donepezil Hydrochloride Tablets 10 mg/day and Placebo. The graph also shows the change from baseline on the ADCS-ADL scale. It appears to be a comparison study on the efficacy of Donepezil Hydrochloride Tablets.*

FDA Label Image

De82e6d7 F231 449a A2aa 91e26eb50774 12

FDA Label Image

De82e6d7 F231 449a A2aa 91e26eb50774 13

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.